gdc
Multiple Myeloma

Sharing Markers with Patients

Jack Aiello talks about the importance of providers helping patients understand the value of markers and how that can positively affect the latter's compliance.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

I think it's really important for patients' treatment team to make sure they do stay on track with medications, and the way the treatment team helps ensure this is to share the information with the patient. How is the patient responding to treatment? How did the doctor know the patient is responding to treatment? The doctor is looking at certain markers.

Share those markers with a patient, so that the patients themselves knows what markers to follow and can understand what the doctor means when the doctor says, "Oh, you've achieved a very good response," or,"You've relapsed."

Those have clinical meanings that are important for patients to understand. When they begin to understand their treatment and the progress of their treatment, they tend to do a much better job of also being in charge of their own medications that they are taking, and become much more self‑aware of the importance of staying on those medications.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country